Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977398 | 0.88 | KMT2A (0.41) | SMPD1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL2978835 | 0.87 | EPAS1 (0.41) | SOS1MEN1KMT2A | |
| SCHEMBL2968831 | 0.86 | KMT2A (0.40) | SMPD1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL6109375 | 0.80 | HTR2A (0.38) | HTR6CD274PDCD1MEN1KMT2A | |
| SCHEMBL6109351 | 0.80 | SLC2A1 (0.40) | SMPD1SOS1KRASSLC2A1 | |
| SCHEMBL2969931 | 0.80 | KDM4E (0.42) | KMT2ADPP7 | |
| SCHEMBL2969371 | 0.79 | PDE4B (0.38) | HTR6CD274MEN1KMT2A | |
| SCHEMBL2969567 | 0.77 | KMT2A (0.43) | HTR6MEN1KMT2A | |
| SCHEMBL2977514 | 0.76 | CASR (0.41) | HTR6MEN1KMT2A | |
| SCHEMBL2977238 | 0.75 | CHRM2 (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776847-B2 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229294-A1 | Benzisothiazoles useful for treating or preventing HCV infection | HAVCR2, ZC3HAV1, MAVS | SMPD1 2927/4885SOS1 3340/4885HTR6 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.